Clinical trial · Observational
EGFR Mutation Targeting Molecular Probe for PET Imaging
Development and Clinical Translation of EGFR Mutation Targeting PET Probe
NCT06641674CI-TRIAL-00081561EGFR-PETnot yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this project, investigators plan to develop a F-18 labeled molecular probe in order to detect the EGFR mutation tumor lessions in patients to identify patients benefiting fromTKIs treatment, and evaluate its efficacy in detecting EGFR Del 19 mutant lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-LF13 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Standard Uptake Value Value
- timeFrame
- 1 year
- description
- The standardized uptake value (SUV) of 18F-LF13 in EGFR mutation lesion measured by PET/CT
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Male and female, aged 18-75 years old (including 18 and 75 years old), ECOG score 0 or 1. 2. Patients could understand and sign the informed consent form voluntarily with good compliance. 3. Patients with histologically or cytologically or clinically confirmed lung cancer with measurable disease. 4. Women had to be using an effective contraceptive method (effective contraceptive means sterilisation, intrauterine hormonal devices, condoms, contraceptives/pills, sexual abstinence, or partner's removal of the vas deferens) during the study and for 6 months after the study. Men should consent to subjects who must use contraception during the study period and for 6 months after the end of the study period. 5. Predicted survival greater than 3 months; Exclusion Criteria: 1. Severe hepatic or renal dysfunction; 2. Pregnant or nursing; 3. Known allergy to the investigational drug or its excipients in study; 4. Unable to comply with the PET/CT imaging procedures; 5. Claustrophobia or other psychiatric disorders; 6. Other conditions deemed unsuitable for participation in the trial;
References
Publications (0)
Data not yet available
No reference posted for this study.